SF1126: Preliminary Phase I data

Preliminary data from a dose-escalation Phase I trial in 8 patients showed that 90-1,110 mg/m 2 IV SF1126 twice weekly for 4 weeks produced 1 case of stable disease. The MTD has not been reached. Data...